Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Wu, Yi-Long, Cheng, Ying, Zhou, Jianying, Lu, Shun, Zhang, Yiping, Zhao, Jun, Kim, Dong-Wan, Soo, Ross Andrew, Kim, Sang-We, Pan, Hongming, Chen, Yuh-Min, Chian, Chih-Feng, Liu, Xiaoqing, Tan, Daniel Shao Weng, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Park, Keunchil, Yang, James Chih-Hsin, Wu, Yi-Long, Liu, Xiaoqing, Liu, Zhe, Lu, Shun, Chen, Xi, Pan, Hongming, Wang, Mengzhao, Yu, Shiying, Zhang, Helong, Zhang, Yiping, Fang, Jian, Li, Wei, Zhou, Jianying, Zhao, Jun, Cheng, Ying, Yang, Chih-Hsin, Chang, Gee-Chen, Chen, Yuh-Min, Hsia, Te-Chun, Chian, Chih-Feng, Yang, Cheng-Ta, Wang, Chin-Chou, Kim, Sang-We, Park, Keunchil, Kim, Dong-Wan, Cho, Byoung Chul, Lee, Ki Hyeong, Kim, Young-Chul, An, Ho Jung, Woo, In Sook, Cho, Jae Yong, Shin, Sang Won, Lee, Jong-Seok, Kim, Joo-Hang, Yoo, Seung Soo, Kato, Terufumi, Shinagawa, Naofumi, Soo, Ross Andrew, Tan, Shao Weng Daniel, Ngo, Lynette Si-Mien, Ratnavelu, Kananathan, Ahmad, Azura Rozila, Liam, Chong Kin, de Marinis, Filippo, Tassone, Pierfrancesco, Molla, Amelia Insa, Calles Blanco, Antonio, Lazaro Quintela, Martin Emilio, Felip Font, Enriqueta, Dingemans, Anne-Marie, Bui, Lynne·2020·The Lancet Respiratory Medicine

Abstract

BACKGROUND We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. METHODS In this open-label, phase 1b/2, multicentre, randomised trial (the INSIGHT study), we enrolled adult patients (≥18 years) with advanced or metastatic NSCLC, and Eastern Cooperative Oncology Group performance status of 0 or 1, from academic medical centres and community clinics in six Asian countries. In phase 1b, patients received oral tepotinib 300 mg or 500 mg plus gefitinib 250 mg once daily. In phase 2, patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification were randomly assigned (initially in a 1:1 ratio and then 2:1 following a protocol amendment) to tepotinib plus gefitinib at the recommended phase 2 dose or to standard platinum doublet chemotherapy. Randomisation was done centrally via an interactive voice-response system. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS) and safety. Subgroup analyses were preplanned in patients with high MET overexpression (IHC3+) or MET amplification (mean gene copy number ≥5 or MET to centromere of chromosome 7 ratio ≥2). Efficacy and patient characteristics were assessed on an intention-to-treat basis and safety was assessed for all patients who received at least one dose of study medication. Low recruitment led to early termination of phase 2, so all analyses are considered to be exploratory. This study is registered with ClinicalTrials.gov, NCT01982955, and the European Union Drug Regulating Authorities Clinical Trials Database, Eudra-CT 2016-001604-28. FINDINGS From Dec 23, 2013, to May 25, 2017, 18 patients were enrolled in phase 1b (n=6 in the 300 mg tepotinib group; n=12 in the 500 mg tepotinib group) and 55 patients in phase 2 (n=31 in the tepotinib plus gefitinib group; n=24 in the chemotherapy group). No dose-limiting toxicities were observed in phase 1b, so tepotinib 500 mg was used as the recommended phase 2 dose. In phase 2, survival outcomes were similar between groups: median PFS was 4·9 months in the tepotinib plus gefitinib group (90% CI 3·9-6·9) versus 4·4 months in the chemotherapy group (90% CI 4·2-6·8; hazard ratio [HR] 0·67, 90% CI 0·35-1·28). Median OS was 17·3 months in the tepotinib plus gefitinib group (12·1-37·3) versus 18·7 months in the chemotherapy group (15·9-20·7; HR 0·69, 0·34-1·41). PFS and OS were longer with tepotinib plus gefitinib than with chemotherapy in patients with high (IHC3+) MET overexpression (n=34; median PFS 8·3 months [4·1-16·6] vs 4·4 months [4·1-6·8]; HR 0·35, 0·17-0·74; median OS 37·3 months [90% CI 24·2-37·3] vs 17·9 months [12·0-20·7]; HR 0·33, 0·14-0·76) or MET amplification (n=19; median PFS 16·6 months [8·3-not estimable] vs 4·2 months [1·4-7·0]; HR 0·13, 0·04-0·43; median OS 37·3 months [90% CI not estimable] vs 13·1 months [3·25-not estimable]; HR 0·08, 0·01-0·51). The most frequent treatment-related grade 3 or worse adverse events were increased amylase (5 [16%] of 31 patients) and lipase (4 [13%]) concentrations in the tepotinib plus gefitinib group and anaemia (7 [30%] of 23 patients) and decreased neutrophil count (3 [13%]) in the chemotherapy group. INTERPRETATION Despite early study termination, in a preplanned subgroup analysis, our findings suggest improved anti activity for tepotinib plus gefitinib compared with standard chemotherapy in patients with EGFR-mutant NSCLC and MET amplification, warranting further exploration. FUNDING Merck KGaA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(20)30154-5

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 258

Metadata

Authors
Wu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., Chen, Y.-M., Chian, C.-F., Liu, X., Tan, D. S. W., Bruns, R., Straub, J., Johne, A., Scheele, J., Park, K., Yang, J. C.-H., Wu, Y.-L., Liu, X., Liu, Z., Lu, S., Chen, X., Pan, H., Wang, M., Yu, S., Zhang, H., Zhang, Y., Fang, J., Li, W., Zhou, J., Zhao, J., Cheng, Y., Yang, C.-H., Chang, G.-C., Chen, Y.-M., Hsia, T.-C., Chian, C.-F., Yang, C.-T., Wang, C.-C., Kim, S.-W., Park, K., Kim, D.-W., Cho, B. C., Lee, K. H., Kim, Y.-C., An, H. J., Woo, I. S., Cho, J. Y., Shin, S. W., Lee, J.-S., Kim, J.-H., Yoo, S. S., Kato, T., Shinagawa, N., Soo, R. A., Tan, S. W. D., Ngo, L. S.-M., Ratnavelu, K., Ahmad, A. R., Liam, C. K., de Marinis, F., Tassone, P., Molla, A. I., Calles Blanco, A., Lazaro Quintela, M. E., Felip Font, E., Dingemans, A.-M., & Bui, L.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2020-11
Volume
8
Issue
11
Pages
1132-1143
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3029971508
Cited by
258
References
29
FWCI
19.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s2213-2600(20)30154-5
The paper
Wu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., Chen, Y.-M., Chian, C.-F., Liu, X., Tan, D. S. W., Bruns, R., Straub, J., Johne, A., Scheele, J., Park, K., . . . Bui, L. (2020). Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30154-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.